Twist Bioscience inks agreements for antibody therapeutic discovery

By The Science Advisory Board staff writers

January 19, 2021 -- Twist Bioscience said that its Twist Biopharma division has signed licensing deals with Serotiny and Applied StemCell aimed at discovering new antibody therapeutics.

Under the deal, Twist Biopharma will collaborate with Serotiny to discover novel chimeric antigen receptors (CAR) for CAR T-cell therapies. The firm will provide Serotiny with custom DNA libraries that encode CARs. Serotiny will then engineer and characterize unique CARs on a large scale to screen for receptor designs that offer improved therapeutic properties and applicability to a wide range of solid tumors, according to the company. Twist will be able to license any technology resulting from the collaboration.

In its partnership with Applied StemCell, Twist will add the firm's Targatt Chinese hamster ovary (CHO) cell lines for screening, selecting, and characterizing any antibodies discovered for its partnered and internal programs.

ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.
Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter